In TCGA data, it was found that upregulated SIGLEC15 expression was associated with longer OS in breast invasive carcinoma, BLCA, THCA, head and neck squamous cell carcinoma and UCEC and with longer relapse-free survival (RFS) in liver hepatocellular carcinoma, ovarian serous cystadenocarcinoma, BRCA, and UCEC. This evidence concerns the gene SIGLEC15 and head and neck squamous cell carcinoma.